Rain Oncology Inc (RAIN)

[tw0122]

Long drought here seen some $RAIN $4.13 + 17%

[Milesblue42]

BRODSKY & SMITH SHAREHOLDER UPDATE:

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc. (NYSE -- AYX), Rain Oncology, Inc. (Nasdaq -- RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq -- CERE)

BALA CYNWYD, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky @bulldop01Toror-4847. There is no cost or financial obligation to you.

Alteryx, Inc. (NYSE -- AYX)

Under the terms of the agreement, Alteryx will be acquired by Clearlake Capital Group, L.P. ("Clearlake") and Insight Partners ("Insight," and together with Clearlake, the "Buyers"). Alteryx stockholders will receive $48.25 per share in cash for each share of Alteryx Class A or Class B common stock that they own. The investigation concerns whether the Alteryx Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Buyers are paying fair value to shareholders of the Company.

https://www.marketwatch.com/press-release/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-alteryx-inc-nyse-ayx-rain-oncology-inc-nasdaq-rain-consolidated-communications-holdings-inc-nasdaq-cnsl-cerevel-therapeutics-holdings-inc-nasdaq-cere-c0309f5f?mod=mw_quote_news_seemore

https://www.brodskysmith.com/cases/alteryx-inc-nyse-ayx/.

[axelvento]

it will still be on the market?
this is the question

[PennyWorld]

Not sure I understand your point. $1.16 is $1.16. Good for some SH.

For me, now I have to swing trade this at a higher range. Buy at 1.10, take profits at s 1.16

[axelvento]

so what? Pathos has established a separate, wholly-owned subsidiary to complete the Transaction. Following the tender offer closing, this subsidiary will be merged into Rain with Rain as the surviving entity of the merger, which will then operate as a separate, wholly-owned subsidiary of Pathos. If the tender offer is successful, the Transaction is expected to close in January 2024.

[Milesblue42]

NEW PR RAIN being bought out

https://www.marketwatch.com/press-release/rain-oncology-enters-into-agreement-to-be-acquired-by-pathos-ai-for-1-16-in-cash-per-share-plus-contingent-value-rights-06ce1004?mod=mw_quote_news_seemore

Press Release
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

[Milesblue42]

Was there a Trading Halt? Or Rumor??

[PennyWorld]

I don't think so. I suspect we'll see another pull back. Profit taking.

[Milesblue42]

Are We getting......Close??

[Monksdream]

RAIN new 52 week low

[Jeritron5100]

Range is tightening. Big move coming soon

[Jeritron5100]

Held 1.23 strong today then a nice late run to 1.30. I like where this is headed. If this first breaks 1.33 and then ultimately 1.37 next leg up will be huge.

[axelvento]

$RAIN 3.42 in cash per share = MULTIBAGGER$

[axelvento]

just waiting for news from Tang. Price will stay in this channel until he is done loading or news breaks on a take over bid.

[axelvento]

I don’t see why this man would invest millions & not do nothing. He did a takeover bid in JNCE 3 months ago with fire results for shareholders. Expecting a pop here very soon

[axelvento]

last arrived-great signal: https://fintel.io/so/us/rain/tang-capital-partners-lp

deep hands.

[Sauerkraut]

Bad P3 Trial anouncmet. But not that bad, still better than everything else in that sector of care.....imo

[PennyWorld]

Reason for PPS crash... failure to meet FDA Phase 3 primary endpoint for MANTRA.
https://finance.yahoo.com/news/rain-oncology-announces-topline-results-120000095.html?.tsrc=rss

However, RAIN does have two other drugs in the pipeline, but unfortunately neither one are in Phase 3 trials.
Pipeline....
https://www.rainoncology.com/pipeline

Fundamentals (debt to equity, O/S, etc) are great, and I see no historical record of an R/S.

IMO RAIN is oversold, but the panic selling may not be complete. It should see a gradual (slow) recovery to the upside over time. But without positive news on the FDA front, I see these price levels as setting a new support level for quite some time.

JMHO

[WARHAMMER]

Knife fell, time to look forward.

[PennyWorld]

Why? Could be a falling knife.

[WARHAMMER]

Who cares. :)

[PennyWorld]

What caused the price to crash in May?

[WARHAMMER]

RAIN - being accumulated-- when "they" are done-- its gonna fly hard

[axelvento]

Tang bought 30% of the float...

[Sauerkraut]

Let's go

[Sauerkraut]

Fore sure, I agree. But I'm not here to protect retail......imo

[TheFinalCD]

TRADING HALF THE FLOAT AND NOT MUCH MOVEMENT IS CRIMINAL


LOL

[Sauerkraut]

Let's go. $2.5+

[axelvento]

Planned MANTRA-2 clinical update at a medical conference in 4Q 2023

PHASE 2- it works very well

Milademetan Shows Early Activity in MDM2-Amplified Advanced Solid Tumors

Notably, activity with the MDM2 inhibitor was observed in patients with heavily pretreated, refractory disease.

[axelvento]

more news to come:

Evaluate avenues to enhance the pipeline through precision oncology program acquisition-

[axelvento]

$RAIN 36.4 million shares of common stock outstanding
Year-end 2023 cash guidance of $75-$80 million, and cash runway to year-end 2026

[axelvento]

There's one piece left-- Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients -

At the data cutoff of October 26, 2022, 17 patients were enrolled. Two unconfirmed partial responses were observed in patients with pancreatic and lung cancer with a tumor regression of 34% and 30% with lung cancer, respectively. Additionally, there was promising tumor regression of 29% in a patient with biliary tract cancer and 27% in a patient with breast cancer; both are receiving continued investigational therapy.

https://www.rainoncology.com/news-press-releases/rain-therapeutics-provides-interim-analysis-of-phase-2-basket-trial-of-milademetan-for-mdm2-amplified-advanced-solid-tumors-mantra-2

[axelvento]

NEW$$$$-Tang Capital Partners Lp ownership in RAIN / Rain Oncology Inc
2023-06-01 - Tang Capital Partners Lp has filed an SC 13D form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,740,341 shares of Rain Oncology Inc (US:RAIN). This represents 14.1 percent ownership of the company.

https://fintel.io/so/us/rain/tang-capital-partners-lp

[TheFinalCD]

also bottom play, stock was $8 with a low float

so watch it

[pitacorp]

it goes up AH because if that SEC report of ownership??

[TheFinalCD]

make it RAIN https://www.sec.gov/Archives/edgar/data/1178579/000120919123033446/xslF345X04/doc4.xml

[nate2028]

$2 Price targets but can’t even hold $1

[nate2028]

Yikes this is in bad shape

[Stock_Gambit]

Yeah. The targets are still much higher than $1….. should see incremental moves soon

[bigbux1]

Thanks, looks like a good entry

[Stock_Gambit]

Didn’t meet their phase 3 goals. But they still have a $16 target.

[bigbux1]

Why the big sell off? Don't see any news...

[surf1944]

https://stockcharts.com/h-sc/ui?s=RAIN&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/RAIN/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/RAIN/opinion

https://finance.yahoo.com/quote/RAIN?p=RAIN

This is why you sell biotech rally's prior to the news release.